Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Selcodebart · DISC-0974

Monoclonal antibody · Antagonist of hemojuvelin (HJV) · developed by Disc Medicine

Phase 2 Most advanced trial
IRON Developer
1 Registered trials

What is Selcodebart?

Selcodebart (DISC-0974) is a humanized monoclonal antibody that binds hemojuvelin, a BMP co-receptor, blocking its signaling and thereby suppressing hepcidin synthesis to increase iron availability. It is studied in anemia and inflammatory bowel disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
DISC-0974
Drug type
Monoclonal antibody
Targets
hemojuvelin (HJV)
Mechanism
Antagonist of hemojuvelin (HJV)
Pathways
BMP-mediated hepcidin regulation, hepcidin synthesis and systemic iron homeostasis, erythropoiesis
Therapy area
Gastroenterology, Hematology
Developer
Disc Medicine, Inc (IRON)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
TQU847U6D9

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07368972 Phase 2 Inflammatory Bowel Disease (IBD) Recruiting IRON

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AnemiaInflammatory Bowel Disease (IBD)Inflammatory Bowel Disease (IBD); Anemia

More from Disc Medicine

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IRON page.

Follow IRON, the company behind Selcodebart

See IRON's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IRON catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.